← Back to trialsNCT02566889
An Efficacy and Safety Study of Infliximab Dose Escalation in Pediatric Participants With Inflammatory Bowel Disease
TERMINATEDPHASE4INTERVENTIONAL
Trial Details
Start: 2016-04Est. Completion: 2019-07
Enrollment target: 53 participants Locations- Phoenix, Arizona, United States
- Los Angeles, California, United States
- San Francisco, California, United States
- Hartford, Connecticut, United States
- Wilmington, Delaware, United States
- Atlanta, Georgia, United States
- Chicago, Illinois, United States
- Peoria, Illinois, United States
- Indianapolis, Indiana, United States
- Shreveport, Louisiana, United States
- Portland, Maine, United States
- Baltimore, Maryland, United States
- Boston, Massachusetts, United States
- Waltham, Massachusetts, United States
- Rochester, Minnesota, United States
- Saint Paul, Minnesota, United States
- Kansas City, Missouri, United States
- Mineola, New York, United States
- New York, New York, United States
- Stony Brook, New York, United States
- Chapel Hill, North Carolina, United States
Other microbiome trials you might be interested in
Inflammatory Bowel DiseaseCrohn's DiseaseUlcerative Colitis
Background:
Inflammatory bowel disease (IBD) is a term used to describe disorders that cause long-term inflammation in …
Bethesda, United StatesEst. completion Jun 1, 2036
Obesity (Disorder)
This randomized crossover clinical trial aims to evaluate the effect of a synbiotic containing Lactobacillus acidophilus…
Huixquilucan, MexicoEst. completion Feb 2, 2027
An Efficacy and Safety Study of Infliximab Dose Escalation in Pediatric Participants With Inflammatory Bowel Disease | MicrobiomeTrialsCleveland, Ohio, United StatesPhiladelphia, Pennsylvania, United StatesPittsburgh, Pennsylvania, United StatesCharleston, South Carolina, United StatesDallas, Texas, United StatesFort Worth, Texas, United StatesFairfax, Virginia, United StatesMadison, Wisconsin, United StatesVancouver, British Columbia, CanadaHalifax, Nova Scotia, CanadaHamilton, Ontario, CanadaLondon, Ontario, CanadaToronto, Ontario, CanadaMontreal, Quebec, CanadaSherbrooke, Quebec, CanadaCompleted
Gastrointestinal Disease Symptoms
The aim of this study is to determine how regular consumption of Synbiotic+, a dietary supplement that contains prebioti…
Fort Collins, United StatesCompleted Aug 1, 2026